4 years ago

PetMedix Raises £27 Million to Revolutionize Pet Healthcare

  • PetMedix, a Cambridge-based startup, has secured £27 million in Series B funding led by Digitalis Ventures and Parkwalk Advisors

  • The funding will enable PetMedix to transition from an R&D-stage to a clinical-stage international organization

  • The company is developing new drugs for pet healthcare, aiming to revolutionize the industry by inventing drugs that can help relieve ailments for pets

  • PetMedix recently completed its first-ever canine trial with one of its antibodies and is excited about the results.

      • ProblemHealthcare

      "Discovering and developing effective drugs for animals is significantly harder than it is for humans, leading to a lack of treatment options for many pet ailments."

      Solution

      "PetMedix develops new antibodies specifically for animals, offering targeted and effective treatments for a variety of pet health issues."

      Covered on